IPSC — Century Therapeutics, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1850119 ·
Last close
$2.25
Market Cap
$405.80M
52W High
$2.64
52W Low
$1.98
ADV30
1,752,311
Next earnings
2026-08-13
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -23,684,000 -21,645,000 326,553,000 51,048,000 61,809,000
Dec 2025 0 -20,651,000 -19,171,000 223,704,000 61,853,000 64,768,000
Sep 2025 0 -29,361,000 -34,422,000 244,717,000 55,515,000 68,369,000
Jun 2025 0 -34,664,000 -32,541,000 284,692,000 56,878,000 74,794,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-94,515,000
Investing CF
$-33,044,000
Financing CF
$126,676,000
CapEx
$-1,571,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-813,562,000
Inventory
Receivables
$667,000
ST Investments
$83,755,000
EBIT TTM
$-108,360,000
Pretax Income TTM
$-107,847,000
Interest Exp TTM
$0
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-101,596,000
Free Cash Flow
$-53,628,000
Enterprise Value
$329,841,600
Total Cash
$134,803,008
Total Debt
$48,025,000
Shares Out
180,354,809
Trailing EPS
$-1.14
Book Value
$1.47
ROE
-42.7%
ROA
-22.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 109,164,000 -10,506,000 -9,580,000 223,704,000 64,768,000 -103,876,000
Dec 2024 6,589,000 -133,810,000 -126,566,000 353,216,000 191,854,000 -110,135,000
Dec 2023 2,235,000 -125,181,000 -136,673,000 360,691,000 175,941,000 -88,348,000
Dec 2022 5,199,000 -123,831,000 -130,932,000 486,544,000 183,806,000 14,052,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.46

Max Pain — expiry 2027-03-19

max pain strike: $2.50 · spot: $2.25 · call oi: 1,460 · put oi: 763
Expected Move to 2027-03-19: ±$3.40 (151.11%) — implied range $-1.15$5.65 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
XFOR X4 Pharmaceuticals, Inc $415.95M $4.41
CMPX Compass Therapeutics, Inc. $419.60M $2.33
AUTL Autolus Therapeutics plc $428.49M $1.61
LXEO Lexeo Therapeutics, Inc. $378.47M $4.82
CCCC C4 Therapeutics, Inc. $448.90M $4.06

News headlines (Yahoo Finance, 1h cache)

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
2026-07-09 12:00 · Yahoo
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
2026-06-22 17:00 · Yahoo
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
2026-06-13 13:38 · Yahoo
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
2026-06-10 18:22 · Yahoo
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
2026-06-08 20:05 · Yahoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
2026-05-14 12:00 · Yahoo
Century Therapeutics Reports First Quarter Financial Results and Business Updates
2026-05-13 12:00 · Yahoo
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
2026-05-01 08:18 · Yahoo
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
2026-04-30 20:05 · Yahoo
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
2026-03-12 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.